肠道微生物衍生胆汁酸在肠道免疫、炎症和肿瘤发生中的作用。
Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis.
机构信息
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Cell Host Microbe. 2022 Mar 9;30(3):289-300. doi: 10.1016/j.chom.2022.02.004.
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal diseases that threaten the health of an increasing number of individuals as their lifestyles become westernized. New insights have been discovered with the development of various omics techniques, revealing that gut-microbiota-derived metabolites play important roles in maintaining intestinal homeostasis and modulating the progression of intestinal diseases from both metabolic and immunological perspectives. Clinical metagenomic and metabolomic studies have revealed links between microbial bile acid (BA) metabolism and IBD and CRC progression. Several BA-derived metabolites were recently been demonstrated to play a role in intestinal immunity, providing fresh insights into how BAs affect the course of IBD and CRC. In this review, we discuss recent studies on the involvement of gut microbiota-derived BAs in intestinal immunity, inflammation, and tumorigenesis along with human omics data to provide prospective insights into future prevention and treatment of IBD and CRC.
炎症性肠病（IBD）和结直肠癌（CRC）是异质性肠道疾病，随着生活方式的西化，越来越多的人受到威胁。随着各种组学技术的发展，人们发现肠道微生物群衍生的代谢物在维持肠道内稳态和从代谢和免疫两个方面调节肠道疾病的进展方面发挥着重要作用。临床宏基因组学和代谢组学研究揭示了微生物胆汁酸（BA）代谢与 IBD 和 CRC 进展之间的联系。最近的研究表明，几种 BA 衍生的代谢物在肠道免疫中发挥作用，为 BA 如何影响 IBD 和 CRC 的病程提供了新的见解。在这篇综述中，我们讨论了肠道微生物群衍生的 BAs 参与肠道免疫、炎症和肿瘤发生的最新研究，以及人类组学数据，为未来 IBD 和 CRC 的预防和治疗提供了前瞻性的见解。
Zotero 插件